Home Capital Broker's Calls

Jiutian to benefit from elevated prices, set to last till 2023: analysts

Jovi Ho
Jovi Ho5/12/2022 10:34 AM GMT+08  • 4 min read
Jiutian to benefit from elevated prices, set to last till 2023: analysts
“Even if the Chinese government approves new supply, it would still require a minimum of nine to 12 months for trials.”
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Limited industry supply is elevating prices for Jiutian Chemical Group’s products, and the squeeze could benefit the company well into next year, says UOB Kay Hian Research analyst Clement Ho.

In a May 11 note, Ho is maintaining “buy” on Jiutian with a higher target price of 18 cents from 16.8 cents previously. The new target price represents an upside of 81.8%.

Jiutian’s 1QFY2022 strong net profit of RMB201.1 million ($41.52 million), up 122.7% y-o-y, came from higher revenue of RMB772.3 million, up 75.8% y-o-y, as average selling prices (ASPs) for dimethylformamide (DMF) and methylamine (MA) remained elevated.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now